

23<sup>rd</sup> June, 2026

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Re: Proceedings of 53<sup>rd</sup> Annual General Meeting of the Company held on 23<sup>rd</sup> June, 2026**

In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform you that the following business was transacted at the 53<sup>rd</sup> Annual General Meeting (AGM) of the Company held through Video Conferencing on 23<sup>rd</sup> June, 2026.

1. Approval and adoption of Standalone Financial Statements as at 31<sup>st</sup> March, 2026, including the Audited Balance Sheet as at 31<sup>st</sup> March, 2026, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon.
2. Approval and adoption of Consolidated Financial Statements as at 31<sup>st</sup> March, 2026, including the Audited Balance Sheet as at 31<sup>st</sup> March, 2026, the Statement of Profit and Loss for the year ended on that date and reports of the Auditors thereon.
3. Confirmation of payment of interim dividend of ₹ 29.00 per equity share of fully paid up face value of ₹ 5.00 each and declaration of final dividend of ₹ 9.00 per equity share of fully paid up face value of ₹ 5.00 each for the financial year ended 31<sup>st</sup> March, 2026.
4. To appoint a Director in place of Samir Mehta (holding DIN: 00061903), Director, who retires by rotation and being eligible, offers himself for re-appointment.
5. Ratification of remuneration of cost auditors of the Company for the year 2026-27.
6. Issuance of Equity Shares including Convertible Bonds / Debentures.

The above business were transacted by Remote e-voting and e-voting at the meeting as required under Companies Act, 2013, Listing Regulations and Ministry of Corporate Affairs General

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – [investorservices@torrentpharma.com](mailto:investorservices@torrentpharma.com)

# **TORRENT** PHARMA

circular no. 20 read with Circular nos. 14 & 17 of 2020 and 03 of 2025. Declaration of Results of Voting along with Scrutinizer's Report and Results of voting as required under Regulation 44(3) of Listing Regulations will be disclosed to the Stock Exchanges separately.

The AGM commenced at 09:30 am and concluded at 10:05 am.

Kindy take note of the above.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

**TORRENT PHARMACEUTICALS LIMITED**

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad - 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – [investorservices@torrentpharma.com](mailto:investorservices@torrentpharma.com)